Discover 381 paid clinical trials in Greenville, South Carolina. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 381
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation
for
Pulmonary Disease, Chronic Obstructive
Location: Greenville SC, Rock Hill SC, Stonecrest GA,
Sponsor: GlaxoSmithKline
Sex: All
Age: 40 - 70+
Code: NCT06959095
Phase 3, Recruiting
Long-Term Stability of the Glide Control Strategy
for
Upper Limb Amputation Above Elbow,
Location: Greenville SC, Anderson SC, Charlotte NC, Leesburg VA,
Sponsor: Infinite Biomedical Technologies
Sex: All
Age: 18+
Code: NCT07222085
Recruiting
A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis
for
Uterine Fibroids, Endometriosis
Location: Greenville SC, West Columbia SC, Norcross GA,
Sponsor: Sumitomo Pharma Switzerland GmbH
Sex: Female
Age: 18 - 50
Code: NCT05862272
Phase 3, Recruiting
Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas
for
Peripheral T-cell Lymphoma
Location: Greenville SC, Atlanta GA, Louisville KY, Hackensack NJ,
Sponsor: CerRx, Inc.
Sex: All
Age: 18+
Code: NCT02495415
Phase 2, Recruiting
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
for
Hematologic Malignancies
Location: Greenville SC, Newnan GA, Chapel Hill NC, Birmingham AL,
Sponsor: Sellas Life Sciences Group
Sex: All
Age: 12+
Code: NCT04588922
Phase 1, Phase 2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
for
Multiple Myeloma
Location: Greenville SC, Atlanta GA, Durham NC, Nashville TN,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18+
Code: NCT07518186
Phase 3, Recruiting
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
for
Breast Neoplasms
Location: Greenville SC, Atlanta GA, Durham NC, Midlothian VA,
Sponsor: Bristol-Myers Squibb
Sex: All
Age: 18+
Code: NCT06926868
Phase 2, Phase 3, Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
for
Breast Neoplasms, Triple Negative Breast Neoplasms,
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
for
Triple Negative Breast Cancer
Location: Greenville SC, Spartanburg SC, Athens GA, Charlotte NC,
Sponsor: Gilead Sciences
Sex: All
Age: 18+
Code: NCT05633654
Phase 3, Recruiting
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Location: Greenville SC, Asheville NC, Atlanta GA,
Sponsor: Heart Rhythm Clinical and Research Solutions, LLC
Sex: All
Age: 18+
Code: NCT04088071
Recruiting
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
for
Multiple Myeloma
Location: Greenville SC, Kettering OH, Norfolk VA, Yakima WA,
Sponsor: Cylene Pharmaceuticals
Sex: All
Age: 18+
Code: NCT01199718
Phase 1, Recruiting
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
for
Relapsing Multiple Sclerosis
Location: Greenville SC, Charlotte NC, Knoxville TN, Atlanta GA,
Sponsor: TG Therapeutics, Inc.
Sex: All
Age: 18 - 65
Code: NCT05877963
Phase 3, Recruiting
A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)
for
Myasthenia Gravis
Location: Greenville SC, New Bern NC, Clearwater FL,
Sponsor: TG Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT07673744
Phase 2, Recruiting
New
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity